Diseases & Conditions
Grants & Contracts
News & Events
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
Currently, people with immune disorders fall outside of guidance for COVID-19 vaccination, as they are typically excluded from vaccine trials.
The goal of this study is to evaluate the safety and efficacy of BIO 300 Oral Suspension to improve lung function in patients that were previously hospitalized with COVID-19 related pulmonary complications.
The primary purpose of NIAID's ACTIV-5/BET study is to evaluate the efficacy of investigational therapeutics in adults hospitalized for COVID-19.
A study to learn how coronavirus affects different organs of the body and the function of the body's immune system.
The primary objectives of this study are to evaluate the safety and reactogenicity of delayed heterologous or homologous vaccine doses after Emergency Use Authorization (EUA)-dosed vaccines and to evaluate the breadth of the humoral immune responses of heterologous and homologous delayed boost re
This NIAID research study focuses on an experimental drug which may help treat COVID-19 by supporting the immune system.
The goal of this study is to learn more about the genetic contributions to the severity of disease in COVID-19. We hope to use this information to develop therapies to reduce the severity of symptoms of COVID-19 in some people.
A research study testing an experimental COVID-19 treatment called anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG).
A study about how SARS-CoV-2, the virus that causes COVID-19, affects the body, specifically how it affects blood cells and the immune system.
A study about long-term medical problems experienced by people who recover from COVID-19 and whether people who recover develop long-term immunity to SARS-CoV-2, the virus that causes COVID-19.
Un estudio de investigación que prueba un tratamiento contra el COVID-19 en fase de investigación conocido como concentrado de inmunoglobulinas de administración intravenosa hiperinmunitarias (hIVIG) anticoronaviral.
Randomized, placebo-controlled, crossover study to assess risk of recurrence of allergic reactions in individuals who had an immediate systemic allergic reaction after 1st dose of an mRNA COVID-19 vaccine and aiming to explore the underlying mechanism(s) of these reactions.
Are you an NIH staff member? If you have some time and have an interest in helping researchers make discoveries about COVID-19 and influenza, we need you!
We are interested in learning about long-term immunity in people who receive COVID-19 and/or flu vaccines.